Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSheba Medical Center

About this trial

Eosinophilic Esophagitis (EoE) is a chronic inflammatory disease characterized by eosinophilic infiltration of the esophageal mucosa, leading to symptoms of dysphagia and food impaction. Currently, upper endoscopy with biopsy is the gold standard for diagnosis and disease monitoring, but it is invasive, costly, and associated with procedural risks. The investigators want to use ultrasound imaging as a non-invasive assessment of esophageal wall thickness as a surrogate marker for mucosal inflammation.

Participants will undergo ultrasound assessment at the same day of endoscopy, and than after 3-6 months (optional). The correlation between US-measured esophageal thickness and histological eosinophil counts will be measured.

Eligibility criteria

Qualifiers

Age ≥18 years.

Suspected or confirmed diagnosis of EoE based on clinical symptoms (e.g., dysphagia, food impaction).

Scheduled for upper endoscopy with biopsies.

Able and willing to consent to participation.

Disqualifiers

Prior esophageal surgery or anatomical abnormalities.

Presence of other gastrointestinal disorders affecting the esophagus (e.g., esophageal cancer, achalasia, Barrett's esophagus).

Pregnancy.

Inability to undergo US due to anatomical or physical limitations.

Trial design

Treatments tested in this trial

  • Trans cervical or abdominal ultrasound

Treatment groups

100 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators